BioSpace News Archive

Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company, is pleased to announce that research on the Company has been initiated by André Uddin, Managing Director Healthcare at Mackie Research Capital Corporation with a speculative buy recommendation and a target price of $0.80/share.

Late-breaking presentation to focus on efficacy and safety data of vupanorsen in patients with hypertriglyceridemia, type 2 diabetes and non-alcoholic fatty liver disease

Terumo Cardiovascular, a global leader in cardiovascular surgery technologies and subsidiary of Japan-based Terumo Corporation, and CytoSorbents Corporation, manufacturer of the CytoSorb® extracorporeal cytokine adsorber, announced an initial collaboration to exclusively sell CytoSorb to hospitals in ten U.S.

Adagio Therapeutics, Inc. announced that Howard Mayer, M.D., Executive Vice President and Head of Research and Development at Ipsen Pharmaceuticals, has joined its board of directors.

NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, announced that the U.S. Food and Drug Administration has cleared its investigational new drug application for the combination of its lead drug candidate, NT-I7, a novel long-acting human interleukin-7, and Kymriah®, a CD19 CAR T-cell therapy, for the treatment of patients with relapsed/refractory large B cell lymphoma.

IV rigosertib did not meet primary endpoint of significantly improved survival versus best supportive care in higher-risk myelodysplastic syndromes (HR-MDS) Onconova will focus on promising pipeline opportunities including with its CDK4/6 + ARK5 inhibitor ON 123300 Onconova to host conference call today at 8:30 a.m. ET NEWTOWN, Pa., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) a biopharmaceutical company focused on discovering and developing novel produ

Inovalon (Nasdaq: INOV), a leading provider of cloud-based platforms empowering data-driven healthcare, today announced that Keith Dunleavy, M.D., chief executive officer and chairman of the board of Inovalon, and Jonathan R. Boldt, chief financial officer of Inovalon, will participate in a virtual fireside chat at KeyBanc Capital Markets’ Future of Technology Series

The global iontophoresis units market is estimated to be influenced by the rising incidences of various diseases like rheumatoid arthritis and hyperhidrosis.

Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces the appointment of Michael C. Dugan, M.D. as Chief Medical Officer and Medical Director.

Four poster presentations will feature clinically relevant efficacy and safety data analyses for WAKIX in adult patients with narcolepsy [24-August-2020] PLYMOUTH MEETING, Pa. and CHICAGO , Aug. 24, 2020 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative thera